Stephen Liu, MD: Initial therapy for this patient is really guided by the molecular profile. This profiling revealed an EML4-ALK fusion. Of note, it also showed very high—100%—PD-L1 expression. While PD-L1 expression predicts response to checkpoint inhibitors, such as pembrolizumab, atezolizumab, and nivolumab, remember that those studies excluded patients with an ALK fusion.
ALK-positive lung cancer is largely an immune nonresponsive tumor. While PD-L1 plays a predictive role for many tumors, it cannot be interpreted in the setting of an ALK fusion. While immunotherapy is an exciting modality of treatment, it really is an inappropriate treatment for patients with an ALK fusion. If given before the proper targeted therapy, it may increase the toxicity of subsequent TKI [tyrosine kinase inhibitor] therapy.
Sequence of treatment is appropriately done with molecular profiling. In this tumor with an EML4-ALK fusion, the preferred treatment is targeted therapy. For patients with brain metastases, brigatinib has performed particularly well. This is critical for ALK-positive lung cancer, which again has a very high tropism for CNS [central nervous system] metastases. Historically we had considered radiation therapy for patients with brain metastases, but we now know that radiation therapy, even focal SRS [stereotactic radiosurgery], has notable sequalae. And in a patient population where survival is measured in years, the toxicity with radiation is quite high.
I prefer systemic therapy with a CNS-penetrant tyrosine kinase inhibitor. The next-generation kinase inhibitors have excellent activity within the brain. I think brigatinib is an excellent choice for someone with brain involvement at the time of diagnosis.
Transcript edited for clarity.
Case: A 57-Year-Old Man with ALK+ NSCLC
Initial Presentation
Clinical Workup
Treatment
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
April 7th 2024An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
April 5th 2024During a Case-Based Roundtable® event, Christine Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non-small cell lung cancer in the first article of a 2-part series.
Read More